You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
News on research and diagnostic developments in neuroscience.
The company said that it will use the funds to build out its CLIA facility and continue developing its blood-based Alzheimer's disease test for the clinic.
The charity also announced a partnership with Sage Bionetworks to establish an online repository for biomarker data generated by grant recipients.
Invitae will provide free genetic testing on a 53-gene panel and counseling to patients suspected of having an LSD to facilitate earlier diagnosis and appropriate treatment.
The findings suggest blood-based testing for tau brain deposits is feasible and could be combined with other blood-based assays to improve Alzheimer's testing.
The company posted Q4 revenues of $15.9 million, up from $10.9 million in Q4 2018, and beat the consensus Wall Street estimate of $14.2 million.